🔥 42 IAS Prelims 2026 Questions Themes Came Directly from Our Expected Topics. Click for the Proof. 🔥 Admissions Open for 21st September GS Batch. Register Now.

GLP-1

GLP-1

GLP-1 (What is it?)

  • GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring incretin hormone produced mainly by specialised cells in the intestine after food intake.
  • It plays an important role in regulating blood glucose, appetite and digestion.
  • GLP-1 is therefore associated with both metabolic regulation and appetite control.
  • Medicines that mimic the action of GLP-1 are known as GLP-1 receptor agonists and are used in the management of conditions such as Type 2 diabetes and obesity.

How does GLP-1 work?

1. Blood Glucose Regulation

  • GLP-1 stimulates the pancreas to release insulin when blood glucose levels rise.
  • It also suppresses the release of glucagon, a hormone that raises blood glucose levels.
  • Thus, GLP-1 contributes to maintaining blood glucose homeostasis.

2. Appetite Control

  • GLP-1 acts on pathways involved in appetite and satiety.
  • It can increase the feeling of fullness, thereby reducing food intake.

3. Slows Gastric Emptying

  • GLP-1 can slow the movement of food from the stomach into the small intestine.
  • This contributes to prolonged satiety and helps regulate post-meal blood glucose.

GLP-1 Receptor Agonists

  • These are medicines designed to mimic the effects of naturally occurring GLP-1.
  • They are used particularly in the treatment of:
    • Type 2 diabetes
    • Obesity and weight management, under medical supervision.
  • Some newer medicines act on multiple metabolic pathways, rather than only the GLP-1 pathway.

Why are GLP-1 Drugs Important?

  • They have emerged as an important development in the management of obesity and metabolic disorders.
  • Their use has also generated discussion about:
    • preservation of lean muscle mass during rapid weight loss;
    • adequate protein and nutrient intake;
    • long-term weight management;
    • accessibility and affordability of obesity treatment.

Conclusion

GLP-1 represents the intersection of endocrinology, diabetes management and obesity treatment. Its growing medical use highlights a broader shift from treating obesity merely as a lifestyle issue towards recognising it as a complex metabolic condition requiring evidence-based and individualised care.

This Concept has been Elaborately Discussed in the following Article:
       Protein in India: From Nutritional Need to Social-Media Fad